13F Holdings
中文EN

NTRR NEUTRA CORP.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1512886 · Fiscal year ends 01/31

Financial factors as of 2023-10-31 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-82.7%
TTM net income YoY-2.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin46.2%
Operating margin-1,457.1%
Net margin-2,723.6%
FCF margin—
EBITDA margin-1,103.4%

Returns

ROE—
ROA-758.7%
ROIC (approx.)—
Asset turnover0.28x

Leverage & solvency

Liabilities / assets3,574.0%
Debt / equity—
Current ratio0.02x
Interest coverage-14.07x

Cash quality & payout

Operating cash flow / net income0.02x
Accruals ratio-743.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-01-31FY20222022-01-31FY20212021-01-31FY20202020-01-31FY20192019-01-31
Income statement
Revenue$67,996$92,014$9,687$6,395—
Cost of revenue$32,690$60,853$42,944——
Gross profit$35,306$31,161-$33,257$6,395—
SG&A expense$227,974$508,482$414,742$400,640$1.71M
Operating income-$297,675-$583,582-$478,665-$394,245-$1.71M
Interest expense$62,063$60,606$121,648$340,701$720,750
Pretax income-$557,894-$632,926———
Income tax$3,523—$3,523$0—
Net income-$561,417-$632,926-$538,892-$695,621-$2.43M
EBITDA-$218,769-$505,797-$447,999——
EPS (basic)——0.000.00-0.16
EPS (diluted)——0.000.00-0.16
Weighted avg. shares (diluted)——1.19B241.54M14.91M
Balance sheet
Cash & equivalents$1,969$1,056$23,308$177,176$0
Receivables——$25——
Inventory$23,846——$3,500—
Current assets$25,815$2,666$24,943$182,334$163,596
PP&E, net$49,360$128,266$165,824——
Total assets$75,175$130,932$190,767$182,334$163,596
Current liabilities$759,639$1.15M$1.00M$1.03M$1.27M
Total liabilities$813,795$1.15M$1.00M$1.03M$1.27M
Shareholders' equity-$773,820-$1.27M-$967,476-$849,490-$1.11M
Shares outstanding2.74B1.78B1.49B616.20M34.13M
Cash flow statement
Operating cash flow-$153,243-$405,615-$412,378-$181,607-$417,000
Capital expenditure—$40,227$196,490——
Free cash flow—-$445,842-$608,868——
Investing cash flow—-$40,227-$196,490——
Financing cash flow$154,156$423,590$455,000$358,783$417,000
Depreciation & amortization$78,906$77,785$30,666——

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.